HealthDay News — Once-daily capsules containing a combination of minoxidil and spironolactone appear to be safe and effective for the treatment of female pattern hair loss (PHL), according to a case-series study published online in the International Journal of Dermatology.

Rodney D. Sinclair, MBBS, MD, from Epworth Hospital in East Melbourne, Australia, presents a case series of 100 women with PHL treated with once-daily minoxidil 0.25 mg and spironolactone 25 mg. Shedding and hair density were scored before and after 12 months of treatment.

Sinclair observed a 0.85 mean reduction in hair loss severity score at 6 months and a 1.3 mean reduction at 12 months. There was also a mean reduction of 2.3 in hair shedding score at 6 months and a mean reduction of 2.6 at 12 months.

There was a drop in blood pressure observed among participants (mean change, −4.52 mm Hg systolic and −6.48 mm Hg diastolic). Eight women experienced side effects, which were generally mild, although 2 who developed urticaria discontinued treatment. No cases of hyperkalemia or any other blood test abnormality were reported.

“Most women noticed a reduction in hair shedding at 3 months and an increase in hair density at 6 months,” Sinclair writes. “Placebo-controlled studies to investigate this further are warranted.”

Sinclair discloses holding a related innovation patent.

Related Articles

Reference

Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironlactone [published online December 12, 2017]. Int J Dermatol. doi: 10.1111/ijd.13838